The shift towards technology and other decentralized approaches in clinical trials has been occurring for years now. The promise of artificial intelligence (AI) in recent years has only accelerated this shift. While the most up-to-date advancements in technology are solving age-old in challenges in trial execution such as long timelines, patient recruitment, and high costs, there are levels of caution and responsibility that must be taken.
In the current landscape, it seems as if there is a solution for almost everything. A number of technology vendors have entered the research space. Stakeholders that are looking to integrate these technologies must have a multi-faceted approach to choosing which are best for their specific studies. There are also regulatory guidelines that must be adhered to.
Over the past year, Applied Clinical Trials has spoken to several industry leaders on the topic of technology in clinical research. In this slideshow, Gareth Dabbs, vice president, global product strategy, IQVIA; Sam Liu, VP of marketing, Vivalink, Ginny Beakes-Read, head, global regulatory policy and intelligence, Johnson & Johnson Innovative Medicine; and Rob DiCicco, vice president, portfolio management, TransCelerate Biopharma share some of their concerns with clinical technology and how they can be addressed.
Image Credit: © Blue Planet Studio – stock.adobe.com